Introduction
Recent studies have shown the therapeutic potential of wild-type p53 (wtp53) gene transfer in nude mice bearing tumors induced by the injection of cancer cells from human head and neck, 1,2 melanoma, 3 glioma, 4 prostate, 5 breast 6,7 and lung. 8, 9 The latter studies provided the basis for a clinical trial of retrovirus-mediated wtp53 gene transfer to tumors of patients with non-small cell lung cancers. 10 The proposed mechanism for the antitumor effect of wtp53 overexpression is the induction of cancer cell apoptosis which has been shown both in vitro and in vivo. 3, [10] [11] [12] However, other mechanisms may also be considered to explain the antitumor effect of wtp53 gene transfer in vivo. The development of an angiogenic phenotype appears essential to tumor progression and it has been suggested that loss of wtp53, a defect common to many tumors, 7 in addition to having a permissive action on the growth of cancer cells may also be associa- 18 February 1998 ted with the development of the angiogenic phenotype. The mechanism for this effect may be a decrease in thrombospondin-1, an angiogenesis inhibitor; this has been shown in fibroblasts 13 and breast cancer cells. 14 Release of an unknown inhibitor of angiogenesis different from thrombospondin has also been reported in glioblastoma cells upon induction of wtp53 expression. 15 Furthermore, wtp53 has a direct effect on the promoter of two angiogenic factors; wtp53 suppresses transcription by the promoter of vascular endothelial growth factor (VEGF) 16 and mutant forms of p53 stimulate the promoter of the insulin-like growth factor 1 receptor (IGF-1R). 17 The objective of this study was to examine the effect of a replication-deficient adenovirus (Ad) encoding the cDNA for human wtp53 (AdCMV.p53) on endothelial cell function in vitro and on angiogenesis in vivo. The results show that Ad-mediated wild-type p53 overexpression in human endothelial cells has no effect on cell proliferation while it inhibits differentiation into capillary-like structures in vitro. This effect cannot be reproduced with conditioned medium from cells infected with AdCMV.p53, suggesting that inhibition of differentiation is not mediated by a secreted factor. Furthermore,
Results

␤-Galactosidase and p53 expression in human umbilical endothelial cells (HUVEC)
In preliminary experiments the ability of Ad vectors to infect HUVEC under our experimental conditions was assessed. Endothelial cells were infected with AdCMV.␤gal (20, 50 and 100 multiplicity of infection (MOI); n = 3 in each group); 48 h later cells were stained with X-gal and the number of positive cells was determined. It was shown that the percentage of cells expressing ␤-gal was 56.3 ± 4.9% at 20 MOI, 79.7 ± 4.0% at 50 MOI, 90.3 ± 1.5% at 100 MOI. Therefore, the vast majority of endothelial cells infected with either 50 or 100 MOI expressed the transgene. In other experiments the ability of AdCMV.p53 to overexpress the transgene in infected HUVEC was examined. Uninfected HUVEC expressed low levels of endogenous p53 which was not modulated by infection with a control Ad vector. However, following infection with AdCMV.p53 there was a marked increase in p53 expression which was still above control 7 days after exposure to the virus (Figure 1a) .
Effect of AdCMV.p53 on HUVEC proliferation
Cell proliferation was assessed 5 days after infection with different concentrations of AdCMV.null and AdCMV.p53 (Figure 1b ). Over this time-period uninfected cells exhibited an eight-fold increase in number. There was no significant inhibition of proliferation of cells infected with either viral vector at 20 and 50 MOI. In contrast, at 100 MOI there was inhibition of HUVEC proliferation versus uninfected control cells which was of similar magnitude for AdCMV.p53-and AdCMV.null-infected HUVEC. FACS analysis was used to determine the percentage of HUVEC in different stages of the cell cycle 5 days after infection (Figure 1c ). By this approach no difference in the cell cycle distribution of cells infected with AdCMV.p53 or AdCMV.null was observed.
Effect of AdCMV.p53 on HUVEC differentiation into capillary-like structures Since the angiogenic process is characterized both by endothelial cell proliferation and differentiation, 18 it was examined whether endothelial cells plated on Matrigel 24 h after infection with AdCMV.p53 retained their ability to differentiate into capillary-like structures. HUVEC which were either not infected or infected with AdCMV.null formed capillary-like structures on Matrigel (Figures 2a and b) , while cells infected with AdCMV.p53 failed to differentiate (Figure 2c ). The dish area occupied by cells, as determined by image analysis, was significantly less in the dishes with AdCMV.p53-infected cells than in either control; furthermore, uninfected and AdCMV.null-infected controls showed no significant difference (Figure 2d ). Since previous studies have shown that wtp53 expression induces the release of inhibitors of angiogenesis 13, 15 the effect of conditioned medium from endothelial cells infected with AdCMV.p53 on HUVEC differentiation was examined. When HUVEC plated on Matrigel were cultured with medium conditioned for 24 h by cells infected with AdCMV.p53, AdCMV.null or uninfected no inhibition of endothelial cells differentiation was observed ( Figure 3 ). These results suggest that the effect of AdCMV.p53 on HUVEC differentiation is not mediated by a soluble factor. Furthermore, HUVEC infected after they had completed the formation of capillary-like structures on Matrigel retained the capillary-like morphology for 40-44 h after exposure to 100 MOI AdCMV.p53 or AdCMV.null (results not shown).
Effect of AdCMV.p53 on angiogenesis in vivo
Since endothelial cell differentiation is an essential component of the angiogenic process, in additional experiments with two different animal models it was examined whether AdCMV.p53 could inhibit angiogenesis in vivo. It has been previously shown 19 that Matrigel
Figure 2 HUVEC differentiation into capillary-like structures. (a) Uninfected HUVEC plated on Matrigel differentiated into capillary-like structures. (b) HUVEC infected with AdCMV.null (100 MOI) 48 h before plating showed capillary-like structures comparable with those formed by uninfected cells. (c) HUVEC infected with AdCMV.p53 (100 MOI) failed to differentiate. (d) Average results of the experiments depicted in panels a-c (n = 3 for each condition). Image analysis showed that infection with AdCMV.p53 markedly inhibited capillary network formation (P Ͻ 0.05 versus both infected and uninfected controls). Results are reported as the percentage of the dish area occupied by cells.
supplemented with bFGF injected subcutaneously into the mouse forms a gel and, within days, cells from the surrounding tissues penetrate the gel and form vascular structures connected with the mouse blood vessels. In the present study, the mouse subcutaneous tissues were injected with either AdCMV.p53, AdCMV.null (5 × 10 7 plaque forming units (p.f.u.)) or saline 3 days before the injection of Matrigel containing bFGF. Evidence was found of a marked inhibition of neovascularization within the Matrigel in the mice previously injected with AdCMV.p53 versus both AdCMV.null-infected and uninfected controls (Figure 4 ). In experiments with a different animal model AdCMV.VEGF 165 was injected into the poorly vascularized rat perirenal fat pad to induce localized neovascularization. 20 This model was used to determine whether AdCMV.p53 could inhibit the angiogenic effect of AdCMV.VEGF 165 when the two vectors were injected together in the rat perirenal fat. It was found that 15 days after injection fat pads coinjected with AdCMV.VEGF 165 and AdCMV.p53 exhibited a number of blood vessels which was approximately 50% less than in fat pads exposed to a similar concentration of AdCMV.VEGF 165 ( Figure 5 ). In the latter group, AdCMV.null was injected instead of AdCMV.p53 to equalize the total Ad vector load between the two groups. Taken together the results show that Ad-mediated wtp53 overexpression inhibits angiogenesis in two different in vivo models.
Discussion
The results of the present study show that Ad-mediated wtp53 gene transfer into endothelial cells inhibits endothelial differentiation in vitro and angiogenesis in vivo. It has been previously shown that fibroblasts from Li-Fraumeni patients which have lost the wild-type allele for p53 exhibit a decreased production of the angiogenesis inhibitor thrombospondin-1. This defect was associated with the switch to the angiogenic phenotype and re-introduction of the wtp53 gene into these fibroblasts enhanced thrombospondin-1 production and restored the anti-angiogenic phenotype. 13 Another study has shown that glioblastoma cells forced to express wtp53 release an unknown inhibitor of angiogenesis. 15 However, the inhibition of differentiation into capillary-like structures on Matrigel reported in the present study was not due to a substance released by AdCMV.p53-infected HUVEC into the conditioned medium. Rather, the results suggest that the effect of AdCMV.p53 to inhibit angiogenesis was due to direct intracellular signaling taking place before the cells completed their differentiation program. However, it cannot be excluded that a putative secreted inhibitor of angiogenesis was not present at a sufficiently high concentration in the media under the experimental conditions of the present study. The molecular mechanism/s responsible for AdCMV.p53-mediated inhibition of HUVEC differentiation into capillary-like structures on Matrigel in vitro and of angiogenesis in vivo remain to be elucidated and different possibilities may be considered. Overexpression of p53 protein may interfere with intracellular signaling due to integrin attachment on Matrigel, 21 the activation of specific proteases 22 and genes associated with growth arrest. 23 In addition, elevated levels of p53 may disrupt the regulated expression of p21 which is necessary for differentiation of HUVEC on Matrigel. 24 It is noteworthy that the anti-angiogenic effect of AdCMV.p53 was not associated with endothelial cell death or cell cycle arrest, a result consistent with that of other studies which have failed to show an apoptotic effect of wtp53 overexpression in noncancer cells. 25, 26 Recent studies suggest that inhibition of angiogenesis may have a significant role in cancer therapy and ongoing clinical trials are evaluating the therapeutic potential of anti-angiogenic drugs in patients with advanced solid tumors. 27 Therefore, the anti-angiogenic action of AdCMV.p53 may provide an antitumor effect 28, 29 that adds to the ability of wtp53 overexpression to induce apoptosis of cancer cells. In fact, the increased tumor cell apoptosis which has been reported for wtp53 gene therapy may, in part, be due to suppression of angiogenesis. 30, 31 This issue may be clinically relevant because Admediated wtp53 gene transfer has several features that make it attractive in cancer therapy: (1) it induces apoptosis of cancer cells; (2) it may slow tumor progression by depriving it of blood supply; and (3) it appears to have no significant damaging effect on noncancer cells which may also be targeted by vectors aimed at overexpressing wtp53. Despite its potential usefulness there are two major limitations to gene therapy with wtp53. Present generation vectors including adenovirus vectors are not cell specific. Therefore, it may be impossible to target metastases until new vectors are developed that localize with a relatively high degree of selectivity in tumors, either in the cancer cells and/or in the vascular cells within the neoplastic growth. Furthermore, present generation vectors induce a significant immune response that prevents effective transduction in vivo after a first exposure to the viral vector. These limitations are being addressed in ongoing studies on adenovirus vector development for gene therapy. Future vectors may incorporate genes that interfere with their recognition by the host immune system and, through modification of the fiber or penton base receptors on the viral capsid, may achieve cell selectivity. 32, 33 It is noteworthy that proliferating endothelial cells 34 and some cancer cells such as melanoma 35 and glioblastoma 36 express high levels of the integrins ␣ v ␤ 3 which is one of the penton base receptors responsible for Ad internalization following cell attachment. 37, 38 Therefore, it is possible that vectors with penton base receptors specific only for ␣ v ␤ 3 may limit gene delivery to tumor endothelium and cancer cells. By this approach adenovirus-mediated wtp53 gene transfer may be closer to being developed into a clinically useful intervention in cancer therapy.
Materials and methods
Adenovirus vectors
The following replication-deficient adenovirus (Ad) vectors were used: AdCMV.p53 expresses human wild-type p53 (a generous gift from Dr B Vogelstein, Johns Hopkins Hospital, Baltimore, MD, USA); AdCMV.VEGF 165 expresses human recombinant VEGF 165 39 and was used to induce angiogenesis in vivo; AdCMV.null carries no insert and was used as a control. AdCMV.␤gal carries the cDNA for Escherichia coli lacZ gene and codes for the enzyme ␤-galactosidase. All Ad vectors were amplified and titrated in 293 cells and purified as previously described. 40 Cell culture and infection Human umbilical vein endothelial cells (HUVEC) (Clonetics, San Diego, CA, USA) were cultured in endothelial basal medium (EBM) supplemented with 2% fetal bovine serum (FBS), 12 g/ml bovine brain extract (BBE), 10 ng/ml human epidermal growth factor (hEGF), 1 g/ml hydrocortisone, 50 g/ml gentamicin and 50 ng/ml amphotericin (all from Clonetics). At the time of infection the medium was removed, the cells were washed with phosphate-buffered saline (PBS; Biofluids, Rockville, MD, USA) and overlaid with serum-free EBM containing 0, 20, 50 or 100 p.f.u. per cell (MOI) of Ad vector. After 60 min the infection medium was removed, the cells were washed with PBS and overlaid with fresh growth medium. HUVEC infected with AdCMV.␤gal were stained with X-gal as previously described. 39 Conditioned medium HUVEC (1 × 10 6 cells in 100 mm dishes) were infected as described above using AdCMV.p53, AdCMV.null (100 MOI) or were not infected. After 24 h the growth medium was removed, the cells were washed with PBS and overlaid with serum-free medium for an additional 24 h. At this time the conditioned medium was collected and concentrated 20 times by centrifugal ultrafiltration through a 3-kDa cut-off membrane (Centriprep-3 concentrators; Amicon, Beverly, MA, USA). At the time of the experiment the concentrated conditioned medium was diluted 1:20 with fresh growth medium and used to assess the differentiation of HUVEC on Matrigel.
Western blot analysis HUVEC were infected as described above with either AdCMV.p53 or AdCMV.null (100 MOI), or were not infected. The cells were collected for Western blot analysis 1, 3, 5 or 7 days after infection. At these time-points, the cells were washed with PBS and lysed with 'buffer A': 10 mm tris-(hydroxymethyl)amino-methane (Tris, ICN, Costa Mesa, CA, USA), 1% SDS (Research Genetics, Huntsville, AL, USA), 1 mm phenylmethanesulfonyl fluoride (PMSF; Boehringer Mannheim, Mannheim, Germany), 10 g/ml aprotinin (Boehringer Mannheim). Cell lysates were centrifuged and protein concentration was determined by the Bradford method (Bio-Rad, Hercules, CA, USA). Proteins were separated on 4-20% trisglycine polyacrylamide gels (Novex, San Diego, CA, USA) and transferred to nitrocellulose membrane (Novex). p53 protein was detected with the ECL system (Amersham, Arlington Heights, IL, USA) after incubation with monoclonal mouse anti-human p53 antibody (p53 DO-1; Santa Cruz Biotechnology, Santa Cruz, CA, USA) followed by incubation with the secondary antibody horseradish peroxidase-conjugated goat anti-mouse IgG (Boehringer Mannheim).
Proliferation assay
For the proliferation assay, 1 × 10 5 HUVEC were seeded in 60 mm dishes and infected as described above with AdCMV.p53 or AdCMV.null (20, 50 or 100 MOI) or were not infected. Subsequently, the infection medium was substituted with standard growth medium and this was changed every 2 days. Cells were harvested 5 days after infection using trypsin/EDTA treatment and cells were counted with a hemocytometer. All experiments were performed in duplicate.
Flow cytometric cell cycle analysis Cell cycle distribution of HUVEC infected with either Ad.CMVp53 or AdCMV.null (50 MOI) or not infected was analyzed using flow cytometry as described. Endothelial cell differentiation in vitro HUVEC (5 × 10 5 in 100 mm dishes) were infected either with AdCMV.p53, AdCMV.null (100 MOI) as described above or were not infected. At the end of infection the medium was substituted with standard growth medium; 48 h later the cells were collected with trypsin/EDTA, resuspended in standard growth medium and plated at a density of 2.5 × 10 5 cells per well in six-well dishes precoated with reconstituted basement membrane proteins (Matrigel) (Beckton Dickinson, Bedford, MA, USA). After 12 h cells were fixed in PBS-buffered 10% formalin. Capillary-like structures formed by HUVEC were quantified by optical imaging (Image-1 analysis system; Universal Imaging Corporation, Westchester, PA, USA). The surface area occupied by the capillary network was quantified in four optical fields per well. The percentage of the tube area in duplicate wells was averaged.
The differentiation of HUVEC was also assessed by plating on Matrigel noninfected cells resuspended in medium conditioned for 24 h by HUVEC infected either with AdCMV.p53 or AdCMV.null (100 MOI) or not infected. After 12 h cells were fixed and the capillary network was analyzed. In other experiments HUVEC were first plated on Matrigel-precoated six-well dishes (2.5 × 10 5 cells per well) in the presence of complete medium. After differentiation into capillary-like structures (6-12 h) the cells were infected with either AdCMV.p53 or AdCMV.null (100 MOI) or were not infected. At the end of infection, the cells were overlaid with complete medium. After 40-44 h the cells were fixed and the capillary network quantified.
Angiogenesis assays in vivo
Two different experimental protocols were used to assess the anti-angiogenic effect of AdCMV.p53 in vivo. In one group of experiments the ability of AdCMV.p53 to inhibit neovascularization within Matrigel plugs containing bovine basic fibroblast growth factor (bFGF; R&D Systems, Minneapolis, MN, USA) was evaluated. 19 In this experimental model cells from the animal's subcutaneous tissue migrate into Matrigel containing bFGF and form vascular structures within the Matrigel plug. To determine whether infection with AdCMV.p53 of the subcutaneous tissues before the injection of Matrigel containing bFGF prevented neovascularization within the Matrigel plug, nude mice (NCI Frederick Cancer Research Center, Frederick, MD, USA) were injected subcutaneously in the left dorsal region with 500 l saline containing either AdCMV.p53 or AdCMV.null (n = 8 for each group; 5 × 10 7 p.f.u.) or no virus (n = 6). Three days later the same area was injected with 500 l Matrigel containing 150 ng bFGF/ml. One week later the Matrigel plugs were removed and fixed in PBS-buffered 4% formalin. In other experiments with 6-month-old Wistar rats from the Gerontology Research Center colony an angiogenic Ad vector coding for the 165 amino acid form of vascular endothelial growth factor (AdCMV.VEGF 165 ) 39 was injected into the perirenal fat tissue as recently described. 20 By this approach a localized increase in blood vessel number was induced which was already apparent 5 days after exposure to the Ad vector. The effect of AdCMV.p53 on angiogenesis was evaluated by coinjecting either this vector or AdCMV.null together with AdCMV.VEGF 165 in the fat tissue.
Surgery was performed under general anesthesia. The abdomen was opened, the right perirenal fat tissue was marked with a silk suture and the Ad vectors, resuspended in a total volume of 300 l, were injected under the suture. The following groups were used: saline, n = 2; AdCMV.null (3 × 10 9 p.f.u.), n = 2; AdCMV.VEGF 165 (1 × 10 9 p.f.u.) coinjected with AdCMV.null (2 × 10 9 p.f.u.), n = 7; AdCMV.VEGF 165 (1 × 10 9 p.f.u.) coinjected with AdCMV.p53 (2 × 10 9 p.f.u.), n = 7. All animals were killed 15 days after the injection and both the right (injected) and the left (uninjected) perirenal fat tissue were removed and fixed in PBS-buffered 4% formalin. In both animal models the angiogenic response was evaluated in two Masson's Trichrome-stained histologic sections for each animal by direct count of vessels in four randomly chosen optical fields per section.
Statistical analysis
The results are presented as mean ± standard error of the mean. Average results were evaluated by one-way analysis of variance (ANOVA) and Bonferroni t test. A P Ͻ 0.05 was taken to indicate statistical significance.
